Your browser doesn't support javascript.
loading
Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.
Wasielewski, Anthony S; Casapao, Anthony M; Jankowski, Christopher A; Isache, Carmen L; Ravi, Malleswari; Kunz Coyne, Ashlan J.
Afiliação
  • Wasielewski AS; UF Health Jacksonville Department of Pharmacy, Jacksonville, Florida, USA.
  • Casapao AM; UF College of Pharmacy, Jacksonville, Florida, USA.
  • Jankowski CA; UF Health Jacksonville Department of Pharmacy, Jacksonville, Florida, USA.
  • Isache CL; UF Health Jacksonville Department of Medicine, Jacksonville, Florida, USA.
  • Ravi M; Department of Infectious Diseases, University of Florida COM-Jacksonville, Jacksonville, Florida, USA.
  • Kunz Coyne AJ; UF Health Jacksonville Department of Pharmacy, Jacksonville, Florida, USA.
Antimicrob Agents Chemother ; : e0075224, 2024 Sep 26.
Article em En | MEDLINE | ID: mdl-39324801
ABSTRACT
Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, P = 0.017).
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article